

Chinese Academy of Sciences Seaweed Nephropathy Second Generation Innovative Medicine Seeks EU Cooperation

Hello:

I am Zhang Jun, the general manager of Dongqian Biological Pharmaceutical (Beijing) Co., Ltd. At present, the second-generation innovative drug with seaweed as raw material and targeting diabetes nephropathy and renal failure in the middle and late stages, which we have cooperated with the Institute of Oceanology of the Chinese Academy of Sciences, has entered the preclinical animal test stage, and the efficacy of the second-generation product in the test is 55% higher than that of the first generation; The total sales of the first generation innovative drugs in 22 years after their launch amounted to 1.4 billion US dollars, ranking among the top kidney disease drugs in China. We plan to register this innovative drug simultaneously in China, Japan, and the European Union, while seeking cooperation from pharmaceutical companies, investment firms, and industry associations in EU countries. We preliminarily estimate that this innovative drug can generate a total sales revenue of 9 billion US dollars in the EU. The project advantages are as follows:

1. Clinical value guarantee. The first generation seaweed kidney disease medicine is the only flagship product of Hong Kong listed company Changlong Pharmaceutical (08049). Currently, it has nearly 500000 long-term users in China and its clinical value is highly trusted.
2. R&D support of the Chinese Academy of Sciences. The second generation innovative drug of seaweed nephropathy has experienced 30 years of technical precipitation from the Institute of Oceanography, Chinese Academy of Sciences. The chief scientist of the company, Zhang Quanbin, is a doctoral supervisor with 107 invention patents under his name. He has won six provincial and ministerial level science and technology awards in China (three first prizes and three second prizes).

3. Capital market recognition. Since the launch of the second-generation innovative drug project for seaweed kidney disease, it has obtained controlling shareholders from China Boji Pharmaceutical (300404) and Yunnan Pharmaceutical Valley (920266), and the two listed companies have jointly invested in angel rounds.

We are currently in negotiations with some cities in the European Union for registration and landing. If your company or association is interested in participating in this investment or promotion, please feel free to contact me. My phone and WeChat are 13511051118, and my email is 13511051118@163.com Thank you again!

Zhang Jun, Dongqian Biopharmaceutical (Beijing) Co., Ltd

April 2026

Board members:

Chief Scientist. Zhang Quanbin, male, 54 years old, doctor, director, researcher and doctoral supervisor of the Marine Medicine Laboratory of the Institute of Oceanology, Chinese Academy of Sciences, has won six provincial and ministerial science and technology awards (three first prizes and three second prizes), involving 107 invention patents, and is the person in charge of the industrialization of the first generation of innovative drugs for seaweed nephropathy and the inventor of the second generation of new drugs. Responsible for research and development work.

2- Executive Director. Zhang Jun, male, 54 years old, holds a Master's degree in Advanced Business Administration from Nankai University and a Master's degree in Business Administration from Royal University of Canada. He has 12 years of experience in middle and senior management of a billion dollar group and 4 years of core management experience. The controlling shareholder and founder of the company are responsible for overall work.

3. Directors. Ma Renqiang, male, 52 years old, holds a PhD in Pharmacy from China Pharmaceutical University. Co founder and Vice President of Boji Pharmaceutical (300404), a Chinese listed company. Responsible for drug research and registration affairs.

4- Director. Luo Cheng, male, 52 years old, with a vocational degree. The controlling shareholder of Yunnan Biovalley (920266), a Chinese listed company. Chairman of Fujian Kangcheng Pharmaceutical Company, responsible for capital and sales affairs.

中国科学院海藻肾病二代创新药寻欧盟合作

您好：

我是东乾生物制药（北京）有限公司总经理张军，目前我们和中国科学院海洋研究所合作的以海藻为原料，以糖尿病肾病、肾病中晚期衰竭为靶点的第二代创新药已经进入临床前动物试验阶段，试验中的第二代产品比第一代疗效增强了 55%；而第一代创新药上市 22 年总销售 14 亿美元，在中国肾病药中名列前茅。我们计划在中国、日本、欧盟三地同步注册这款创新药，同时寻找欧盟国家的制药企业、投资公司、行业协会合作，我们初步预判该创新药在欧盟可以形成 90 亿美元的总销售额。项目优势如下：

1、临床价值保障。第一代海藻肾病药为香港上市公司长龙药业（08049）唯一主打产品，目前在中国有近 50 万用户长期服用，临床价值深受信赖。

2、中国科学院研发保障。海藻肾病二代创新药历经中国科学院海洋研究所 2 代人 30 年技术沉淀。公司首席科学家张全斌为博士生导师，名下涉及 107 项发明专利，获中国省部级科技大奖六项（1 等奖 3 次，2 等奖 3 次）。

3、资本市场认可。海藻肾病二代创新药项目启动以来，已获中国博济医药（300404）、云南医药谷（920266）控股股东，两家上市公司联合投资天使轮。

我们目前正在与欧盟的一些城市洽谈注册落地，如贵公司、协会有兴趣参与这项投资或推广，欢迎联系我，我的电话及微信：13511051118，邮箱 13511051118@163.com。再次致谢！

东乾生物制药（北京）有限公司 张军

二零二六年四月